

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/047.072	01/15/2002	Ralph M. Steinman	MER-011DIV/112917.138US2	7452	
23483	7590 08/05/2002				
HALE AND DORR, LLP			EXAMINER		
60 STATE ST BOSTON, M			EWOLDT, GERALD R		
			ART UNIT	PAPER NUMBER	
			1644	^	
			DATE MAILED: 08/05/2002	L	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

Applicant(s)

10/047,072

Sreinman et al.

Examiner

G.R. Ewoldt

Art Unit **1644**



	The MAILING DATE of this communication appears or	n the cover shee	et with t	the correspondence address		
	or Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.						
- If the p - If NO p - Failure - Any rep	eriod for reply specified above is less than thirty (30) days, a reply within the eriod for reply is specified above, the maximum statutory period will apply and to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of this patent term adjustment. See 37 CFR 1.704(b).	I will expire SIX (6) M application to become	ONTHS from ABANDO	om the mailing date of this communication. INED (35 U.S.C. § 133).		
Status						
1) 🗌	Responsive to communication(s) filed on			·		
2a) 🗌	This action is FINAL . 2b) \mathbf{X} This action	on is non-final.				
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposit	tion of Claims					
4) 💢	Claim(s) <u>1-8</u>			is/are pending in the application.		
4	a) Of the above, claim(s)					
	Claim(s)					
	Claim(s)					
7) 🗆	Claim(s)					
8) 💢	Claims <u>1-8</u>					
	ition Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are	a) 🗆 accepted	or b)	\square objected to by the Examiner.		
	Applicant may not request that any objection to the dr	awing(s) be held	d in abe	yance. See 37 CFR 1.85(a).		
11)	The proposed drawing correction filed on	is:	a) 🗌 a	approved b) \square disapproved by the Examiner.		
If approved, corrected drawings are required in reply to this Office action.						
12)	12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) □ All b) □ Some* c) □ None of:						
	1. \square Certified copies of the priority documents have	e been received	d.			
	2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the priority do application from the International Burea	iu (PCT Rule 1)	7.2(a)).			
	ee the attached detailed Office action for a list of the					
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).						
a) The translation of the foreign language provisional application has been received.						
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Peper No(s)						
_	otice of References Cited (PTO-892) otice of Draftsperson's Patent Drawing Review (PTO-948)			nt Application (PTO-152)		
2) Notice of Draftsperson's Patent Drawing Review (P10-948) 5) Notice of Informal Patent Application (F10-132) 3) Information Disclosure Statement(s) (PT0-1449) Paper No(s) 6) Other:						
~, □ »	The state of the s					

Serial No. 10/047,072 Art Unit 1644

DETAILED ACTION

- 1. This application contains inventions drawn to patentably distinct species. Applicant is required under 35 U.S.C. § 121 to elect:
- A) a **specific** cytokine or combination of cytokines, such as one of those listed in Claim 6,
- B) and list all Claims readable thereon including those subsequently added. Currently Claims 1-8 are generic.
- 2. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

The different cytokines comprise significantly different biological properties as they relate to the growth of dendritic cells, e.g., TNF- α is thought to be required for the growth of human dendritic cells whereas other cytokines such as IL-12 are not. Therefore, the species are independent and patentable over one another.

- 3. Applicant is advised that the response to this requirement to be complete must include an election of the species to be examined even though the requirement be traversed.
- 4. Any inquiry concerning this communication from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973.

G.R. Ewoldt, Ph.D.

Patent Examiner

Technology Center 1600

August 5, 2002